AlphAIAlphAI — Financial news for AI agents
tradingview.comAUG 251 min read$PAHC

PAHC Q4'26 Earnings: EPS estimate is 0.71 USD

Phibro Animal Health (PAHC) will report Q4'26 earnings on August 26, with revenue expected at $381.18M and EPS at $0.71, according to estimates.

Original reporting
tradingview.com
Published Aug 25, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 4:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
PAHC Q4'26 Earnings: EPS estimate is 0.71 USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$PAHCNeutralMed
01

Why it matters

The guidance sets market expectations; deviation at release could drive volatility.

02

Market read

First disclosure of Q4'26 guidance; relevant for short‑term traders monitoring earnings releases.

03

What to watch

Potential impact of commodity price changes on animal health demand.

Relevance 7/10Novelty 7/10Timing: pre‑market Aug 26

Background

PAHC is a U.S. listed animal health company; the article provides only the upcoming earnings estimate.

Company-level read

Ticker impact

$PAHCNeutralMedium confidence
Context

Q4'26 earnings estimate of $0.71 EPS and $381.18M revenue to be released after market close on Aug 26.

Expected impact

Potential modest move up or down depending on actual results versus estimate.

Evidence & confidence

Guidance is the first disclosed figure for this quarter; market will price in expectations and react to the actual report.

Market effects

Sector

Animal health sector may see slight re‑rating based on PAHC guidance.

Regional

U.S. small‑cap investors will watch the release.

Global

Limited to niche livestock health market.

Counterpoint

What could challenge this read

If actual results beat the modest guidance, PAHC could rally sharply.

Key entities

  • Company
    Phibro Animal Health Corporation

    U.S. animal health products provider (ticker PAHC).

Read at source← All news

Related articles

SEP 5
$PAHCMedAI 8/10

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.

yahoo.com3 min
SEP 1
$PAHCHighAI 8/10

Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year

Phibro Animal Health (PAHC) reported fiscal 2026 net sales of $1.5B, adjusted EBITDA up 39% to $255M, and EPS up 48% to $3.22. The growth was driven by a recent acquisition and organic growth across segments. Guidance for fiscal 2027 expects slower growth with net sales of $1.55B-$1.6B and EBITDA of $258M-$268M. Free cash flow was $9.9M due to inventory buildup, with debt at $737.9M and a leverage ratio of 2.9x EBITDA.

yahoo.com3 min
AUG 31
$PAHCHighAI 8/10

Phibro (PAHC) Q4 2026 Earnings Call Transcript

Phibro (PAHC) reported Q4 2026 net sales of $396.7M, up 5%, and adjusted EBITDA of $255M, up 39% YoY. Full-year sales reached $1.518B, up 17%, with adjusted EBITDA up 39%. CEO Dani Bendheim highlighted strong performance across segments, including a 20% increase in Mineral Nutrition sales. The company provided fiscal 2027 guidance, expecting net sales of $1.55B-$1.6B and adjusted EBITDA of $258M-$268M. Phibro also announced the closure of a Chicago facility and discussed regulatory uncertainties

yahoo.com2 min
AUG 27
$PAHCHighAI 8/10

Phibro Animal Health Q4 Earnings Call Highlights

Phibro Animal Health (PAHC) reported Q4 and full-year 2026 results, with legacy MFA and other revenue up 4%, Nutritional Specialties up 9%, and vaccine revenue up 14%. The company expects fiscal 2027 sales of $1.55B-$1.60B and adjusted EBITDA of $258M-$268M, with growth driven by acquired MFA products and international demand. However, Brazil regulatory uncertainty and higher input costs may impact performance. Phibro also plans to close its Chicago Heights facility, expecting $15M-$20M in annua

yahoo.com2 min
AUG 26
$PAHCHigh

PHIBRO ANIMAL HEALTH CORP (PAHC): Results of Operations and Financial Condition

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ For Immediate Release ​ Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance ​ TEANECK, N.J., August 26, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) tod

SEC EDGAR 8-K3 min